论文部分内容阅读
目的探讨细胞因子诱导的杀伤细胞(CIK)联合小剂量白介素2(IL-2)治疗恶性体腔积液的疗效及对免疫指标的影响。方法选取2008年1月1日至2012年12月1日收治的143例恶性体腔积液患者,采用CIK细胞联合小剂量IL-2治疗的67例患者为观察组,单独采用IL-2治疗的76例患者为对照组。对比两组患者的临床疗效和免疫指标变化。结果观察组患者临床有效率为79.1%,对照组临床有效率为61.8%,差异有统计学意义(P<0.05)。两组患者治疗前免疫指标CD+3、CD+4、CD+4/CD+8和NK细胞差异无统计学意义(P>0.05)。治疗后所有患者免疫指标均明显高于治疗前,组间比较显示,治疗后观察组患者的免疫指标水平均高于对照组患者,差异有统计学意义(P<0.05)。结论 CIK细胞联合小剂量IL-2治疗恶性体腔积液的疗效显著,症状发作和体腔积液明显较少,可以明显升高CD+3、CD+4、CD+4/CD+8和NK细胞等免疫指标水平。
Objective To investigate the efficacy of cytokine-induced killer (CIK) combined with low-dose interleukin-2 (IL-2) in the treatment of malignant effusion and its effect on immune parameters. Methods A total of 143 patients with malignant effusion admitted from January 1, 2008 to December 1, 2012 were enrolled in this study. 67 patients treated with CIK cells combined with low-dose IL-2 were selected as the observation group and treated with IL-2 alone 76 patients as control group. The clinical efficacy and immune changes of two groups were compared. Results The clinical effective rate was 79.1% in observation group and 61.8% in control group, the difference was statistically significant (P <0.05). There was no significant difference in the immune parameters of CD + 3, CD + 4, CD + 4 / CD + 8 and NK cells between the two groups before treatment (P> 0.05). After treatment, the immune indexes of all the patients were significantly higher than those before treatment. The comparison between the two groups showed that the immunological indexes in the observation group were higher than those in the control group after treatment (P <0.05). Conclusion CIK cells combined with low dose of IL-2 in the treatment of malignant effusions have obvious curative effect. Symptoms and effusion of CIK cells are obviously less, which can significantly increase CD + 3, CD + 4, CD + 4 / CD + 8 and NK cells Such as the level of immune indicators.